Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Inhibiting FKBP5 might alleviate obstetric antiphospholipid syndrome by regulating macrophage polarization.

ABSTRACT: Inhibiting FKBP5 might alleviate obstetric antiphospholipid syndrome by regulating macrophage polarization.

PROVIDER: PRJNA1195595 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR31642682_1.fastq.gz	Fastqsanger.gz
	SRR31642682_2.fastq.gz	Fastqsanger.gz
	SRR31642683_1.fastq.gz	Fastqsanger.gz
	SRR31642683_2.fastq.gz	Fastqsanger.gz
	SRR31642684_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 16

Similar Datasets

Inhibiting FKBP5 might alleviate obstetric antiphospholipid syndrome by regulating macrophage polarization.

Project description:The disturbance of immune balance at the maternal-fetal interface is a significant contributor to obstetric antiphospholipid syndrome (OAPS); however, the precise mechanisms underlying this disturbance remain unclear. This study investigates the immune regulatory role of FK506-binding protein 5 (FKBP5) to elucidate its molecular mechanisms in pathological pregnancies associated with OAPS. We conducted RNA sequencing (RNA-seq) analysis and immune cell typing on decidual tissue from OAPS patients and healthy controls. The results indicated that the FKBP5 gene and inflammation-related pathways were significantly expressed in the maternal-fetal interface of OAPS patients, characterized by an increase in M1 (iNOS+/CD86+) macrophages and a decrease in M2 (Arg-1+/CD206+) macrophages. In vitro experiments demonstrated that FKBP5 promotes M1-like polarization of macrophages via the JAK1/STAT1 pathway while inhibiting M2-like polarization through the PPARγ/STAT6 pathway. Using a macrophage-trophoblast cell co-culture model, we found that FKBP5-induced abnormal macrophage polarization at the maternal-fetal interface negatively impacted the migration, invasion, and proliferation of trophoblast cells. In a mouse model of OAPS, the knockout of FKBP5 regulated the abnormal polarization of macrophages between M1 and M2 phenotypes, facilitated epithelial-to-mesenchymal transition (EMT), and mitigated antiphospholipid antibodies (aPLs)-mediated placental pathological damage. Notably, SAFit2, a small molecule inhibitor of FKBP5, effectively improved adverse pregnancy outcomes in OAPS mice. The immune microenvironment imbalance at the maternal-fetal interface, driven by FKBP5-regulated macrophage polarization, constitutes a critical immunological basis for aPLs-mediated placental damage. Therefore, FKBP5 presents a potential therapeutic target for OAPS.

2025-04-07 | GSE283798 | GEO

TPPU alleviate cartilage degradation in temporomandibular joint osteoarthritis by inhibiting M1 macrophage polarization through the EETs/IL-17/NF-KB signaling pathway

Project description:TPPU alleviate cartilage degradation in temporomandibular joint osteoarthritis by inhibiting M1 macrophage polarization through the EETs/IL-17/NF-KB signaling pathway

| PRJNA1200801 | ENA

Corticosteroid-induced chromatin loop dynamics at the FKBP5 gene

Project description:FKBP5 is a long glucocorticoid-inducible gene implicated in psychiatric disorders. To investigate the complexities of chromatin interaction frequencies at the FKBP5 topologically associated domain (TAD), we deployed fifteen one-to-all chromatin capture viewpoints near gene promoters, enhancers, introns, and CTCF-loop anchors. This revealed a ‘one-TAD-one-gene’ structure encompassing the FKBP5 promoter and its enhancers. The FKBP5 promoter and its two glucocorticoid-stimulated enhancers roam the entire TAD while displaying subtle cell type-specific interactomes. The FKBP5 TAD consists of two nested CTCF loops that are coordinated by one CTCF site beyond the FKBP5 polyadenylation site and another in its 8th intron, 61 kb further. Loop extension correlates with transcription increases through the intronic CTCF site. This is efficiently compensated for, since the short loop is restored even under high transcription regimes. The boundaries of the FKBP5 TAD consist of divergent CTCF sites, harbor multiple smaller genes and are resilient to glucocorticoid stimulation. Interestingly, both FKBP5 TAD boundaries harbor H3K27me3-marked heterochromatin blocks that may reinforce them. We propose that cis-acting genetic and epigenetic polymorphisms underlying FKBP5 expression variation are likely to reside within a 240 kb region that consists of the FKBP5 TAD, its left sub-TAD, and both its boundaries.

2023-10-15 | GSE136034 | GEO

Gene profiling reveals specific molecular pathways in the pathogenesis of atherothrombosis in Antiphospholipid syndrome, Systemic Lupus Erythematosus and Lupus with Antiphospholipid Syndrome

Project description:The present gene expression array study of comparative gene profile in monocytes from patients with primary Antiphospholipid Syndrome, Systemic Lupus Erythematosus and Lupus with Antiphospholipid Syndrome demonstrates that the gene expression profiling allows the segregation of these highly related autoimmune diseases, with specific signatures explaining the pro-atherosclerotic, pro-thrombotic and inflammatory changes.

2014-03-12 | GSE50395 | GEO

Transcriptomic Analysis of Placenta Affected by Antiphospholipid Antibodies: Following the TRAIL of trophoblast death

Project description:Antiphospholipid antibodies, a maternal risk factor for preeclampsia, increase shedding of necrotic trophoblast debris from the placenta, leading to endothelial dysfunction. Using Affymetrix HGU133 Plus 2 microarrays, we found changes in the transcriptome of placental explants treated with antiphospholipid antibodies including seven mRNAs encoding for genes BCL2L1, MCL1, PDCD2L, FASLG, SEMA6A, PRKCE and TRAIL that are involved in the regulation of apoptosis. Quantitative real-time RT-PCR and immunohistochemistry confirmed a reduction in TRAIL expression. These results may help to understand how antiphospholipid antibodies affect trophoblast cell death and how the antibodies could contribute to the pathogenesis of preeclampsia. Three different first-trimester placentas (8-8.5 weeks gestation) were dissected into 6 explants each and cultured either with antiphospholipid antibodies (25ug/mL) or untreated media for 16h. RNA was extracted from treated placental explants and Affymetrix HGU133 Plus 2 arrays were conducted to investigate changes in mRNA expression. Untreated: 1UNT, 2UNT, 3UNT Antiphospholipid antibody treatment: 1APL, 2APL, 3APL Biological replicates: 1, 2, 3

2012-02-27 | E-GEOD-36083 | biostudies-arrayexpress

Antiphospholipid antibodies induce Proinflammatory and Procoagulant Pathways in Endothelial cells.

Project description:Antiphospholipid syndrome (APS) is an autoimmune thrombophillia characterized by recurrent thrombotic events and/or pregnancy morbidity in the presence of antiphospholipid antibodies detected either as anti-cardiolipin, anti-β2 Glycoprotein I (anti-β2GPI) or Lupus anticoagulant (LA). Endothelial deregulation characterizes the syndrome. To address the gene expression changes occurring in the endothelial cells in the context of APS, we performed transcriptome analysis of Human Umbilical Vein Endothelial cells (HUVECs) stimulated with anti-β2GPI-β2GPI complexes.

2023-05-24 | GSE143506 | GEO

Targeting the tissue factor coagulation initiation complex prevents antiphospholipid antibody development

Project description:Antiphospholipid antibodies (aPL) in primary or secondary antiphospholipid syndrome (APS) areis a major cause for acquired thrombophilia. Here we test the effect of specific inhibition of the TF coagulation initiation complex with nematode anticoagulant protein c2 (NAPc2) on the activation of monocytes by aPL. NGS data show that aPL-induced proinflammatory and prothrombotic activation of monocytes, but not interferon regulated gene induction is prevent by NAPc2.

2024-03-21 | GSE252972 | GEO

Transcriptomic Analysis of Placenta Affected by Antiphospholipid Antibodies: Following the TRAIL of trophoblast death

2012-02-27 | GSE36083 | GEO

Fkbp5 Gene Deletion: Impacts on Circadian Rhythmicity and Brain Proteomics in Aged Mice

Project description:FKBP51, also known as FK506-binding protein 51, is a molecular chaperone and scaffolding protein with significant roles in regulating hormone signaling and stress responding. Genetic variants in FKBP5, which encodes FKBP51, have been implicated in a growing number of neuropsychiatric disorders, which has spurred efforts to target FKBP51 therapeutically. However, the molecular mechanisms by which FKBP51 influences the pathways affected in these disorders are not fully understood. Protein changes in Fkbp5 KO mice, as measured by histology and proteomics, revealed alterations in a brain region- and sex-dependent manner.

2024-09-05 | PXD049439 | Pride

Targeting the tissue factor coagulation initiation complex prevents antiphospholipid antibody development.

Project description:Antiphospholipid antibodies (aPL) in primary or secondary antiphospholipid syndrome (APS) are a major cause for acquired thrombophilia. Here we show that specific inhibition of the TF coagulation initiation complex with nematode anticoagulant protein c2 (NAPc2) prevents the the development of persistent aPL and circulating phospholipid-reactive B1 cells in latent viral infection and lupus prone MRL-lpr mice. NGS mRNA profiling of splenic DC in lupus mice treated with NAPc2 versus saline control uncovered a suppression of dendritic cell activation in the spleen.

2024-03-21 | GSE252397 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data